

# Zhiya Yu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8972854/publications.pdf>

Version: 2024-02-01

30  
papers

5,447  
citations

236925

25  
h-index

477307

29  
g-index

31  
all docs

31  
docs citations

31  
times ranked

8599  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. <i>Science</i> , 2022, 375, 877-884.	12.6	156
2	Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors. <i>Cancer Immunology Research</i> , 2022, 10, 932-946.	3.4	52
3	Identification and Validation of T-cell Receptors Targeting <i>RAS</i> Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5084-5095.	7.0	26
4	An engineered IL-2 partial agonist promotes CD8+ T cell stemness. <i>Nature</i> , 2021, 597, 544-548.	27.8	94
5	Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. <i>Science</i> , 2020, 370, 1328-1334.	12.6	273
6	Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies. <i>Cancer Cell</i> , 2020, 37, 818-833.e9.	16.8	96
7	Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models. , 2020, 8, e000210.		27
8	Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens. <i>Clinical Cancer Research</i> , 2020, 26, 1267-1276.	7.0	69
9	Host conditioning with IL-1 $\beta$ improves the antitumor function of adoptively transferred T cells. <i>Journal of Experimental Medicine</i> , 2019, 216, 2619-2634.	8.5	51
10	Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1805-1817.	4.2	40
11	T cell stemness and dysfunction in tumors are triggered by a common mechanism. <i>Science</i> , 2019, 363, .	12.6	355
12	The transcription factor c-Myb regulates CD8+ T cell stemness and antitumor immunity. <i>Nature Immunology</i> , 2019, 20, 337-349.	14.5	113
13	An effective mouse model for adoptive cancer immunotherapy targeting neoantigens. <i>JCI Insight</i> , 2019, 4, .	5.0	36
14	Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. <i>Journal of Clinical Investigation</i> , 2019, 129, 1109-1114.	8.2	193
15	Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System. <i>Cell Reports</i> , 2018, 22, 3175-3190.	6.4	35
16	Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. <i>JCI Insight</i> , 2018, 3, .	5.0	110
17	Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche. <i>Cell</i> , 2016, 166, 1117-1131.e14.	28.9	203
18	Constitutive Lck Activity Drives Sensitivity Differences between CD8+ Memory T Cell Subsets. <i>Journal of Immunology</i> , 2016, 197, 644-654.	0.8	18

#	ARTICLE	IF	CITATIONS
19	Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. <i>Cancer Immunology Research</i> , 2016, 4, 204-214.	3.4	175
20	miR-155 augments CD8 <sup>+</sup> T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic $\text{I}^3_{\text{c}}$ cytokines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 476-481.	7.1	99
21	Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. <i>Molecular Therapy</i> , 2015, 23, 1380-1390.	8.2	88
22	Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest. <i>Cancer Immunology Research</i> , 2015, 3, 37-47.	3.4	24
23	Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. <i>Oncotarget</i> , 2015, 6, 9073-9085.	1.8	54
24	Identification of the Genomic Insertion Site of Pmel-1 TCR $\hat{1}$ and $\hat{2}$ Transgenes by Next-Generation Sequencing. <i>PLoS ONE</i> , 2014, 9, e96650.	2.5	24
25	T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6973-6978.	7.1	203
26	A human memory T cell subset with stem cell-like properties. <i>Nature Medicine</i> , 2011, 17, 1290-1297.	30.7	1,547
27	Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. <i>Blood</i> , 2010, 116, 3875-3886.	1.4	301
28	Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8 <sup>+</sup> T cells. <i>Journal of Clinical Investigation</i> , 2005, 115, 1616-1626.	8.2	815
29	Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. <i>Journal of Clinical Investigation</i> , 2004, 114, 551-559.	8.2	104
30	Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. <i>Journal of Clinical Investigation</i> , 2004, 114, 551-559.	8.2	66